leadf
logo-loader
viewCytoDyn Inc.

CytoDyn links up with Chinese medical services firm to utilize leronlimab against the coronavirus

The companies will work together to find potential uses for leronlimab in fighting the coronavirus

People wearing medical masks
Leronlimab has the potential to enhance the cellular immune response to the coronavirus and could potentially be used in concert with other retroviral therapies

CytoDyn Inc (OTCMKTS:CYDY) has signed a nonbinding letter of intent with Chinese medical services provider Longen China Group to develop and license its drug leronlimab as a treatment for coronavirus.  

The companies will work together to find potential uses for leronlimab in fighting the coronavirus, known officially as 2019-nCoV, which has killed more than 900 people in China and infected at least 40,000, according to CNN

“We are thrilled to partner with Longen, one of the largest medical service providers in China, to develop leronlimab as a potential treatment for coronavirus and cancer,” CytoDyn CEO Nader Pourhassan said in a statement. “By working together and leveraging our expertise, we hope to bring effective and safe treatments to patients suffering from these deadly diseases.”

READ: CytoDyn files Phase 2 basket trial with lead drug leronlimab for treating all solid cancer tumors

Leronlimab has the potential to enhance the cellular immune response to the coronavirus, the company said, and could potentially be used in concert with other retroviral therapies.

“The biotech and healthcare communities desperately need to identify new and potential treatments to limit the spread of 2019-nCoV as quickly as possible,” Longen CEO Wenbao Bi said. “We support CytoDyn’s efforts to explore the potential uses of leronlimab to help patients who are suffering from 2019-nCoV. We also look forward to working with CytoDyn to address indications within oncology.”

Leronlimab has previously produced compelling clinical data from three patients participating in the Company’s Phase 1b/2 trial for the treatment of metastatic triple-negative breast cancer. 

The US Food and Drug Administration has granted leronlimab Fast Track designation for two potential uses: for metastatic triple-negative breast cancer and as a combination therapy with HAART for HIV-infected patients.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Quick facts: CytoDyn Inc.

Price: 3.55 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $2.02 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn addresses WSJ & SeekingAlpha articles, calls on investors to pay...

CytoDyn Inc. (OTCQB:CYDY) CEO Nader Pourhassan addresses the recent articles published by the Wall Street Journal and SeekingAlpha, in regards to its participation in Operation Warp Speed. Pourhassan says shareholders should pay attention to the group's fundamentals, adding to 'only buy the...

3 weeks, 4 days ago

2 min read